Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression.

Roncevic J, Djoric I, Selemetjev S, Jankovic J, Dencic TI, Bozic V, Cvejic D.

Pathology. 2019 Jan;51(1):55-61. doi: 10.1016/j.pathol.2018.10.008. Epub 2018 Nov 27.

PMID:
30497805
2.

Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.

Jendrzejewski J, Liyanarachchi S, Nagy R, Senter L, Wakely PE, Thomas A, Nabhan F, He H, Li W, Sworczak K, Ringel MD, Kirschner LS, de la Chapelle A.

Thyroid. 2016 Sep;26(9):1276-84. doi: 10.1089/thy.2015.0665. Epub 2016 Jul 22.

4.

Correlation between polymorphisms of BRAF gene and papillary thyroid carcinoma.

Jiang R, Zhao C, Xu H, Zhao M, Sun X, Wang X, Song W.

Clin Endocrinol (Oxf). 2016 Mar;84(3):431-7. doi: 10.1111/cen.12804. Epub 2015 Jun 1.

PMID:
25916409
5.

[Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].

Jiang XL, Zhang H, Chen YL, Peng L.

Zhonghua Bing Li Xue Za Zhi. 2017 Mar 8;46(3):160-165. doi: 10.3760/cma.j.issn.0529-5807.2017.03.004. Chinese.

PMID:
28297755
6.

Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.

Wu G, Zhou Y, Li T, Guo J, Zhou Z.

J Int Med Res. 2013 Jun;41(3):816-24. doi: 10.1177/0300060513481923. Epub 2013 May 17.

PMID:
23685894
7.

Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.

Meng XY, Zhang Q, Li Q, Lin S, Li J.

J Int Med Res. 2014 Jun;42(3):619-27. doi: 10.1177/0300060513505485. Epub 2014 Mar 26.

PMID:
24670538
8.

Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.

Wang N, Jiang R, Yang JY, Tang C, Yang L, Xu M, Jiang QF, Liu ZM.

J Mol Histol. 2014 Aug;45(4):391-9. doi: 10.1007/s10735-013-9557-9. Epub 2013 Nov 26.

PMID:
24276590
9.

Interleukin 27 -964A > G genetic polymorphism and serum IL-27p28 levels in Chinese patients with papillary thyroid cancer.

Zhang S, Gao X, Wang Y, Jia J, Zhang Q, Ji Z.

Tumour Biol. 2015 Sep;36(10):8207-11. doi: 10.1007/s13277-015-3570-4. Epub 2015 May 21.

PMID:
25994572
10.

Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration.

Marecko I, Cvejic D, Selemetjev S, Paskas S, Tatic S, Paunovic I, Savin S.

Croat Med J. 2014 Apr;55(2):128-37.

11.

Association between single nucleotide polymorphisms of upstream transcription factor 1 (USF1) and susceptibility to papillary thyroid cancer.

Yuan Q, Bu Q, Li G, Zhang J, Cui T, Zhu R, Mu D.

Clin Endocrinol (Oxf). 2016 Apr;84(4):564-70. doi: 10.1111/cen.12832. Epub 2015 Aug 14.

PMID:
26052935
12.

1513A>C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters.

Dardano A, Falzoni S, Caraccio N, Polini A, Tognini S, Solini A, Berti P, Di Virgilio F, Monzani F.

J Clin Endocrinol Metab. 2009 Feb;94(2):695-8. doi: 10.1210/jc.2008-1322. Epub 2008 Nov 18.

PMID:
19017759
13.

Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer.

Çil E, Kumral A, Kanmaz-Özer M, Vural P, Doğru-Abbasoğlu S, Altuntaş Y, Uysal M.

Mol Biol Rep. 2014 May;41(5):3091-7. doi: 10.1007/s11033-014-3169-7. Epub 2014 Jan 28.

PMID:
24464184
14.
15.

Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma.

Šelemetjev S, Ðoric I, Paunovic I, Tatic S, Cvejic D.

Am J Clin Pathol. 2016 Nov 1;146(5):594-602. doi: 10.1093/ajcp/aqw184.

PMID:
27806941
16.

Polymorphisms in selected DNA repair genes and cell cycle regulating genes involved in the risk of papillary thyroid carcinoma.

Halkova T, Dvorakova S, Sykorova V, Vaclavikova E, Vcelak J, Vlcek P, Sykorova P, Kodetova D, Betka J, Lastuvka P, Bavor P, Hoch J, Katra R, Bendlova B.

Cancer Biomark. 2016 Jun 7;17(1):97-106. doi: 10.3233/CBM-160622.

PMID:
27314298
17.

Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma.

Luo D, Chen H, Li X, Lu P, Long M, Peng X, Lin S, Tan L, Zhu Y, Ouyang N, Li H.

Int J Oncol. 2017 Oct;51(4):1209-1218. doi: 10.3892/ijo.2017.4100. Epub 2017 Aug 23.

PMID:
28848996
18.

No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma.

Wang Y, Fang S, Wei L, Wang R, Jin X, Wen D, Li Y, Guo W, Wang N, Zhang J.

Lung Cancer. 2005 Aug;49(2):155-61.

PMID:
15949868
19.

Pri-Mir-34b/C and Tp-53 Polymorphisms are Associated With The Susceptibility of Papillary Thyroid Carcinoma: A Case-Control Study.

Chen P, Sun R, Pu Y, Bai P, Yuan F, Liang Y, Zhou B, Wang Y, Sun Y, Zhu J, Zhang L, Gao L.

Medicine (Baltimore). 2015 Sep;94(38):e1536. doi: 10.1097/MD.0000000000001536.

20.

Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population.

Erdogan M, Karadeniz M, Berdeli A, Tamsel S, Ertan Y, Uluer H, Yilmaz C, Tuzun M, Kabalak T, Ozgen AG.

J Endocrinol Invest. 2007 May;30(5):411-6.

PMID:
17598974

Supplemental Content

Support Center